trending Market Intelligence /marketintelligence/en/news-insights/trending/hR9ZwsDC-aJSnjDh1U-bdg2 content esgSubNav
In This List

US FDA approves Eli Lilly, Boehringer Ingelheim's type 2 diabetes drug

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


US FDA approves Eli Lilly, Boehringer Ingelheim's type 2 diabetes drug

The U.S. FDA approved Eli Lilly & Co. and Boehringer Ingelheim's Synjardy XR for adults with type 2 diabetes.

Synjardy XR is a combination of two drugs formulated to be taken once a day. The approval was based on clinical trials examining the co-administration of empagliflozin and metformin, alone or in combination with sulfonylurea in the treatment of adults with type 2 diabetes.

The drug is co-marketed by Eli Lilly and Boehringer Ingelheim. Synjardy XR is the eighth FDA-approved treatment from Eli Lilly and Boehringer's partnership.